Low Body Weight as a Risk Factor for Apalutamide-related Cutaneous Adverse Events
Sign Up to like & getrecommendations! Published in 2022 at "AntiCancer Research"
DOI: 10.21873/anticanres.15682
Abstract: Background/Aim: Therapeutic strategies for prostate cancer are currently undergoing a paradigm shift due to the advent of next-generation androgen receptor inhibitors. Among these inhibitors, apalutamide is regarded as a key drug because of its effectiveness.… read more here.
Keywords: cutaneous adverse; adverse events; apalutamide related; related cutaneous ... See more keywords